



Pharmacy and Therapeutics Committee

October 19, 2016 12:00pm -5:00 pm
Gold Room, 3rd Floor
701 E. Jefferson Phoenix, AZ 85034

AGENDA

Teleconference: 1-877-820-7831 Passcode: 960711

Agenda Topics

Noon

Welcome and Introductions: Sara Salek, MD, Chief Medical Officer, AHCCCS

- 8-16-16 P&T Minutes Review and Vote

AHCCCS and BH Drug Lists

12:15

Supplemental Rebate Class Review:

1. Inhaled Antibiotics
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony: None
 - c. Public Testimony: None

2. Cytokine and CAM Antagonists
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony:
 - i. Michelle Mui: Cimzia-UCB
 - ii. Scott Budsberg: Enbrel-Amgen
 - iii. Laura Hill: Humira-Abbvie
 - iv. Marlies Ozias: Orencia-BMS
 - v. Carrie Johnson: Otezla-Celgene
 - vi. Rick Smith: Xeljanz-Pfizer
 - c. Public Testimony: None

3. Epinephrine – Self Injected
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony
 - i. Roger Stephens: EpiPen-Mylan
 - c. Public Testimony: None

4. Growth Hormone
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony:
 - i. Patrick Archer: Genotropin-Pfizer
 - ii. Jignesh Patel: Norditropin-NovoNordisk
 - c. Public Testimony: None

5. Long-Acting Narcotic Analgesics
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony
 - i. Jerod Downing: Butrans-Purdue Pharma
 - ii. Laurence Ikeda: Embeda-Pfizer
 - iii. Jerod Downing: Hysingla ER- Purdue Pharma
 - iv. Jerod Downing: Oxycontin-Purdue Pharma
 - c. Public Testimony
 - i. Matthew Rhodes: Arrowhead Health Centers

	<ul style="list-style-type: none"> 6. Bevespi Aerosphere <ul style="list-style-type: none"> a. Clinical review: Sarah Martinez: Provider Synergies 7. Makena <ul style="list-style-type: none"> a. Clinical review: Sarah Martinez: Provider Synergies 8. Executive Session 9. Class Votes
3:00	Follow up Oral Oncology Subcommittee: <i>Suzi Berman, AHCCCS</i>
3:10	Follow up on HIV Subcommittee: <i>Suzi Berman, AHCCCS</i> <ul style="list-style-type: none"> a) HIV Therapeutic Class and Single Agent Reviews b) Genvoya PA status
3:20	New Drug Reviews: Non-Supplemental Rebate Class: <i>Suzi Berman, AHCCCS</i> <ul style="list-style-type: none"> a) Xiidra - Lifitegrast ophthalmic solution b) Zynbryta - Daclizumab c) Ocaliva - Obeticholic acid d) Briviact - Brivaracetam
4:00	Opioid 7-day Quantity Limitation - <i>Shana Malone, AHCCCS</i>
4:30	Pill Splitting : <i>Dr. Chakmakian, CMO, United Health Care</i>
4:55	Agenda Items for the January 25, 2017 P&T: The Inhaled Glucocorticoids Drug class will be reviewed at the next P&T Committee.
5:00	Meeting Adjourned

2017 Meeting Dates:

Monday, Thursday, April 13, 2017, Tuesday, July 18, 2017, & Thursday, October 12, 2017